BioMed Realty, L.P. Prices $400 Million Offering Of 2.625% Senior Unsecured
Notes Due 2019
SAN DIEGO, April 15, 2014
SAN DIEGO, April 15, 2014 /PRNewswire/ --BioMed Realty Trust, Inc. (NYSE:
BMR) today announced that its operating partnership subsidiary, BioMed Realty,
L.P., priced a public offering of $400 million aggregate principal amount of
2.625% Senior Notes due 2019 (the "Notes"). The Notes were priced at 99.408%
of the principal amount to yield 2.752% to maturity. The Notes will be senior
unsecured obligations of the operating partnership and will be fully and
unconditionally guaranteed by BioMed Realty Trust, Inc. The offering is
expected to close on April 23, 2014, subject to customary closing conditions.
The operating partnership intends to use the net proceeds from the offering to
repay a portion of the outstanding indebtedness under its unsecured line of
credit and for other general corporate and working capital purposes.
Deutsche Bank Securities Inc., Wells Fargo Securities, LLC, KeyBanc Capital
Markets Inc. and U.S. Bancorp Investments, Inc. acted as Joint Book-Running
Managers for the offering.
The registration statement relating to these securities has become effective
by rule of the Securities and Exchange Commission. The offering was made only
by means of a prospectus and a related prospectus supplement, copies of which
may be obtained by contacting Deutsche Bank Securities Inc., Attention:
Prospectus Group, 60 Wall Street, New York, New York 10005-2836, by calling
toll-free 1-800-503-4611 or by emailing prospectus.CPDG@db.com; or Wells Fargo
Securities, LLC, Attention: Capital Markets Client Support, 1525 West W.T.
Harris Blvd., NC0675, Charlotte, North Carolina 28262, by calling toll-free
1-800-326-5897 or by emailing email@example.com.
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy any of these securities, nor shall there be any sale of
such securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of such state or other jurisdiction.
About BioMed Realty Trust
BioMed Realty, with its trusted expertise and valuable relationships, delivers
optimal real estate solutions for biotechnology and pharmaceutical companies,
scientific research institutions, government agencies and other entities
involved in the life science industry. BioMed Realty owns or has interests in
properties comprising approximately 17.3 million rentable square feet.
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 based on current
expectations, forecasts and assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially. These risks
and uncertainties include, without limitation: general risks affecting the
real estate industry (including, without limitation, the inability to enter
into or renew leases, dependence on tenants' financial condition, and
competition from other developers, owners and operators of real estate);
adverse economic or real estate developments in the life science industry or
the company's target markets; risks associated with the availability and terms
of financing, the use of debt to fund acquisitions, developments and other
investments, and the ability to refinance indebtedness as it comes due;
failure to maintain the company's investment grade credit ratings with the
ratings agencies; failure to manage effectively the company's growth and
expansion into new markets, or to complete or integrate acquisitions and
developments successfully; reductions in asset valuations and related
impairment charges; risks and uncertainties affecting property development and
construction; risks associated with tax credits, grants and other subsidies to
fund development activities; risks associated with downturns in foreign,
domestic and local economies, changes in interest rates and foreign currency
exchange rates, and volatility in the securities markets; ownership of
properties outside of the United States that subject the company to different
and potentially greater risks than those associated with the company's
domestic operations; risks associated with the company's investments in loans,
including borrower defaults and potential principal losses; potential
liability for uninsured losses and environmental contamination; risks
associated with the company's potential failure to qualify as a REIT under the
Internal Revenue Code of 1986, as amended, and possible adverse changes in tax
and environmental laws; and risks associated with the company's dependence on
key personnel whose continued service is not guaranteed. For a further list
and description of such risks and uncertainties, see the reports filed by the
company with the Securities and Exchange Commission, including the company's
most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The
company disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.
SOURCE BioMed Realty Trust, Inc.
Contact: Rick Howe, Senior Director, Corporate Communications, (858) 207-5859,
Press spacebar to pause and continue. Press esc to stop.